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CObjectives: TheNational Institute forHealth andClinical Excellence (NICE)
SingleTechnologyAppraisal (STA)process intheUnitedKingdomwasestab-
lished in 2005 in order to provide guidance on new technologies as close to
their launch as possible. TheNICE recommended timeframe for completion
of anSTA is34weeks.Thepurposeof this studywas tomap thefirst 95STAs
to collect information on a range of issues including timelines and appraisal
decisions. Methods: A mapping tool was devised to collect information
rom the NICE Web site. Data were analyzed by calculating frequencies.
imple descriptive statistics were applied where appropriate.
esults: Ninety-five STAs were included in the analysis. Almost one-
hird (30/95) initially identified topics did not go on to be appraised often
ue to licensing issues. Timelines weremeasured for 29 completed STAs.
ight (28%) of thesewere completedby37weeksand20 (69%) by42weeks.
hen STAswith appealswere excluded, 31% (8/26)were completed by 37 O
y of S
al So
oi:10.1016/j.jval.2011.06.007eeks and 85% (22/26) by 42 weeks. The incremental cost-effectiveness
atios reported by manufacturers were consistently lower than those es-
imatedby theevidence reviewgroups. Inall, 76% (38/50) of the completed
TAs resulted in an approval. Conclusions: The NICE Web site enabled
ccess to almost all necessary information, although electronic docu-
ents were sometimes difficult to locate. One-third of the referred topics
ere suspended or terminated. The NICE STA process is slower than ini-
ially anticipated and this is primarily due to events outside of NICE’s
irect control.
eywords: critique, data collection, decision making, health care deci-
ion making, United Kingdom.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The National Institute for Health and Clinical Excellence (NICE)
single technology appraisal (STA) process was introduced in early
2005 as a mechanism to provide prompt appraisal of technologies
for use within the National Health Services in England and Wales
so that national guidance for new products could be produced as
close as possible to their launch and more quickly than the exist-
ingmultiple technology appraisal (MTA) process [1]. Pressure for a
faster system was exerted by patients, manufacturers, and health
care decision makers, and so speeding up the appraisal process
became a political imperative [2,3].
The STA process specifically focuses on a technology for a single
indication, although there may be more than one comparator to the
new product. The key differences between the MTA and the STA pro-
cesses, besides the duration of the appraisal, is that the principal evi-
dence-based informing the STA process is submitted by themanufac-
turer in the form of themanufacturer submission (MS); whereas in the
MTAprocess, a systematic review of the clinical and cost-effectiveness
evidence and a cost-effectiveness analysis is carried out independently
by the assessment group (AG).
When the STA process was initially introduced, concerns were
raised that basing decisions on submissions from the manufacturers
may represent a less robust process for producing guidance on the use
* Address correspondence to: Eva Kaltenthaler, ScHARR, Universit
E-mail: e.kaltenthaler@sheffield.ac.uk.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.of health technologies than theMTAprocess [4] and issues continue to
be raised regarding their rigour and timeliness [5,6]. In addition, there
hasbeenon-goingdebate regarding theburdenofproofwithin theSTA
process [7,8], that iswhether it should be the responsibility of theman-
ufacturer or NICE.
The STA process consists of three distinct phases. Phase 1 is
the initiation of the STA and evidence submission (including the
decision problem). Phase 2 is the evidence review (including initial
clarification), and Phase 3 is the appraisal. Phase 1 begins after the
scoping phase has been completed and NICE has received formal
referral from the Secretary of State for Health. This article deals
mainly with the latter two stages. According to the NICE STA pro-
cess guide [1], the time from issue of the final scope to issue of the
final appraisal determination (FAD) is expected to be 34 weeks or
less (when there is no appeal). In the original STA process guide [9]
this was stated to be 35 weeks. In reality, there can be more than
one FAD issued for an appraisal and these timelines were set up
taking the issue of only one FAD into consideration. NICE requires
themanufacturer to present an evaluation of the clinical and cost-
effectiveness of the technology using decision analytic ap-
proaches as outlined in the NICE guide to the methods for STAs
[10] in the form of theMS. TheMS is then critically appraised by an
independent evidence review group (ERG) to identify strengths,
weaknesses, and gaps in the evidence presented. The resultant
heffield, 30 Regent Court, Regent Street, Sheffield S1 4DA, UK.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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1159V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 5 8 – 1 1 6 5ERG reports are then considered as a part of the evidence submit-
ted to the appraisal committee (AC) when they convene to make
their decision on the use of the technology. Other evidence exam-
ined by the AC includes the MS and evidence submissions from
patient representatives and professional bodies. Table 1 shows a
ummary of the extensive STAprocess timelines thatNICE aims to
eet from formal referral through to the issue of NICE guidance.
The processes for conducting an STA have been in a continu-
us state of change since their introduction in 2005. For example,
coping workshops were not included in the initial STA process
ut were added as the process evolved to allow for consultation
nd to ensure that all aspects of the STA topic had been explored
nd defined [11]. Currently, provisional STA topics are identified
nd NICE manages the topic selection process on behalf of the
epartment of Health (DH) and thenworkswith the DH to develop
draft scope for each topic. The scope defines the disease, the
atients, and the technology covered by the appraisal and the
uestion(s) it aims to address. Consultees and commentators are
rovided an opportunity to comment on the draft scope and a
copingworkshop is held to discuss key issues related to the scope
nd also to discuss whether the decision question would be best
ddressed through the STA orMTAprocess. Following this consul-
ation process the DH makes a formal decision to refer topics to
ICE and the STA timelines are then established and the manu-
acturer is invited to prepare a submission for the appraisal.
To date, the STA process has been an evolutionary journey
ith multiple iterations and changes over time. This study re-
orted here is part of a larger project that appraised the STA pro-
ess in its wider context [12]. This report maps the first 4 years of
he process (95 STAs) through the collection of information on a
ange of issues including STA timeframes, reasons for delay, and
ppraisal decisions.
Methods
A mapping tool was devised using an EXCEL (Microsoft Corpora-
tion, Redmond,WA) spread sheet to collect information on a range
of topics for each STA. Data were analyzed by calculating frequen-
Table 1 – Summary of STA process timelines.
Weeks Key
0 NICE requests manufacturer or sponsor’s eviden
2 NICE receives manufacturer or sponsor’s submis
decision problem
9 NICE receives manufacturer or sponsor’s evidenc
and consultee statements
11 NICE sends request for clarification to manufactu
17 NICE receives ERG report
18 NICE sends ERG report to manufacturer or spons
19 NICE compiles evaluation report and sends it to
21 Appraisal Committee meeting to develop ACD or
23 ACD consultation starts
24 NICE published ACD on its Web site for public co
25 NICE sends FAD to consultees and commentator
27 ACD consultation ends
29 Appraisal Committee meeting to develop FAD
30 Anticipated publication (if no appeal received)
34 NICE sends FAD to consultees and commentator
37 Close of appeal period (if no appeal, NICE usually
Source: NICE [1].
ACD, appraisal consultation document; ERG, evidence review group; F
Clinical Excellence; STA, single technology appraisal; CHMP, Commitcies and simple descriptive statistics were applied where appro-priate. All STAs which had been considered by NICE up to and
including March 2009 were included in the mapping exercise. Ini-
tial data were collected during August 2009 and a final review of
NICE decisions for the 95 STA topics was performed in February
2011. The list of STAs was provided by the National Institute for
Health Research evaluation, trials and studies coordinating centre
(NETSCC). Information regarding each STA was obtained from the
NICE Web site [13] and included: referral date, final scope date,
NICE disease category, appraisal consultation document (ACD),
incremental cost-effectiveness ratios (ICERs) reported by theman-
ufacturer and the ERG, FAD, and appeal details.
Three reviewers (DP, AB, EK) extracted the data. Cross checking
of the data was performed early in the data collection exercise
(after reviewers had each extracted data on five appraisals). Also,
after data extraction was completed, a sample of nine STAs was
taken and data were checked by a second reviewer who had not
completed the initial data collection in order to verify that data
extraction had been undertaken in a consistent manner by all
reviewers. Discrepancies were settled through discussion. Where
data were not available on the NICEWeb site, for example, referral
date in some cases, the information was requested from NETSCC.
For the purposes of this article, a completed STAwas defined as an
STA that had received a final decision in the form of a FAD from
NICE on the technology being considered. Any STA that had pre-
viously received a final decision from NICE and was subsequently
withdrawn was not included in the completed STA category.
Theexactdate (day/month/year)wasnotprovidedondocuments
such as the final scope and FAD. The date was usually provided in
month/year format only on the documents with the exact date of
upload available on the NICE Web site. Where the month of issue
differedon the scopeor FADdocument fromthemonth statedon the
NICE Web site for the document upload, the month listed on the
document was used and the 28th day of the month was chosen as
the “exact date” in order to perform analyses between the different
stages in the STA project timeline. Where the month agreed be-
tween the document and date of upload on the NICEWeb site, the
exact date listed as the upload date on theNICEWeb sitewas used.
For both scenarios, these decisionsmeant that the analyses would
nts in STA timelines
bmission NICE invites consultee statements
f NICE requests nominations of experts from all
non-manufacturer/sponsor consultees and
commentators
mission Start of ERG report consultation
r sponsor
fact check
ppraisal Committee attendees (excluding public)
CHMP positive opinion required at this point
before appraisal can proceed
ation
working days for consultees to appeal)
working days for consultees to appeal)
ishes guidance approximately 6 weeks later)
nal appraisal determination; NICE, National Institute for Health and
r Medicinal Products for Human Use.eve
ce su
sion o
e sub
rer o
or for
the A
FAD
nsult
s (15
s (15
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AD, fiunderestimate rather than overestimate the time taken between
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1160 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 5 8 – 1 1 6 5stages in the STA process. Similarly, when the exact date of refer-
ral was not available, the 28th day of the month the STA was
referred was selected for each referral date. Simple descriptive
statistics such as calculating the mean and range were applied
where appropriate.
Results
A total of 95 STA topic titles were identified from commencement
of the STA process in 2005 up to and including March 2009. Figure
shows the status of the 95 identified topics.
Suspensions and terminations
Thirty of the 95 identified topics (32%) were listed as either sus-
pended or terminated. Twenty-two STAs were listed as sus-
pended. In two of these STAs, the MS had been submitted and the
ERG report had already been received by NICE at the time of sus-
pension. Reasons for suspension listed on the NICE Web site in-
cluded the following: the drug not yet launched (n  2); the indi-
cation for the drug was uncertain (n  1); regulatory or licensing
issues prohibited consideration by the AC (n 11); no MS received
(n  1); further data were awaited by the manufacturer (n  3);
referral to MTA process (n  1); and no reason given (n  3). Eight
STAs were listed as terminated. Three of these passed through
topic selection butwere not referred toNICE for consideration, two
were terminated because the MS had not been submitted to NICE
and reasons explainingwhy three STAs had been terminatedwere
unavailable from the NICE Web site. In addition, guidance for one
STA [14] was issued and subsequently withdrawn by NICE. As of
February 2011, 50 STAs were completed and 14 were still in prog-
Fig. 1 – Flow of 95 topics. STA, single technology appraisal.ress.Timelines
The recommended timeframe for completion of an STA has
changed over time and has ranged between 34 and 35 weeks [1,9].
or the purpose of this study we added a grace period to allow for
oliday periods and other delays, making a cut off point for a
ompleted on time STA of 37weeks (if there is no appeal). Of the 95
TAs that moved into the formal appraisal process, 36 were cate-
orized as completed STAs in August 2009, that is a FAD had been
ssued, and 28 were categorized as in progress. The results pre-
ented for timelines below refer to these 36 STAs.
Referral to scope
The time period between the referral date and issue of the final
scope ranged considerably between 4.4 and 83 working weeks for
the 36 completed STAs. Where referral and scope dates were both
available (n  26), the average number of working weeks from
referral to issue of the final scope was 15.3 weeks.Wewere unable
to determine the length of time for seven completed STAs because
scopes were not issued for the initial tranche of STAs.
Final scope to FAD (including appeals)
Including all STAs for which there was a scope (n  29), the mean
length from issue of the final scope to production of the FAD was
43.3 weeks (26.2–99.8 weeks). In terms of time from issue of final
scope to FAD, 28% (8/29) of the STAsmet the 35- to 37-week target.
A further 41% (12/29) were delayed by an additional 2 to 5 weeks. If
these are taken as a group then 69% (20/29) were completed by 42
weeks.
Final scope to FAD (excluding appeals)
Ten STAs had no scope and/or appeal hearing, which left 26 com-
pleted STAs without appeals for which timeline calculations were
possible. The mean length of time taken from issue of final scope
to FADwas 40.4weeks (range 26.2–96weeks). In terms of time from
issue of final scope to FAD, 31% (8/26) of the STAs met the 35- to
37-week target. A further 54% (14/26) were delayed by an addi-
tional 2 to 5 weeks. If these are taken as a group then 85% (22/26)
were completed by 42 weeks.
Scope to submission of MS
The average number of working weeks from issue of the scope to
submission of the MS for the 36 completed STAs was 9.7 weeks
(range –1 to 36.4 weeks). Five scopes were issued more than 10
weeks before the manufacturer was due to submit the MS. The
time taken from issue of scope to final FAD was therefore length-
ened and completion of an STA within a target period of 37 weeks
unlikely.
Submission of MS to completion of ERG report
The NICE process guide stipulates that ERG teams will be given a
minimum of 8 weeks to complete their critique of the MS [1]. For
the 36 completed reports, the mean number of working weeks
between the submission of the MS by the manufacturer and the
completion of the ERG report was 10.5 weeks (range 8.2–23.8
weeks). The first AC meeting is typically scheduled to take place 4
weeks after the ERG report has been submitted. For the 36 com-
pleted reports, the mean number of working weeks between ERG
report submission and first AC meeting was 5.4 weeks (range 3.4–
11.2 weeks). The mean number of working weeks between sub-
mission of the MS and issue of the FAD (first FAD if more than one
was issued) including appeals was 33.55 weeks (range 17.8–123
weeks); excluding appeals this became 30.5weeks (range 19.2–59.8
weeks).
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It was difficult to compile an accurate categorization of the iden-
tified STAs using the 21 topic categories from the NICE Web site
because a number of the topics were listed in more than one cat-
egory. No STAs were undertaken for three of the NICE topic cate-
gories: ear and nose; mouth and dental; and surgical procedures.
These are shown in Table 2.
What is clear is that almost half (46/95) of the STAs dealt with
technologies related to cancer treatments. A total of 27 manufac-
turers participated in the STA process during this period – 13man-
ufacturers had only been involved in 1 appraisal; 7 had been in-
volved in 2 appraisals; 6 had been involved in between 3 and 6
appraisals; and 1 had contributed to 12 appraisals.
Reported ICERs
At the time of data extraction (August 2009), 43 STAs including
completed and in process STAs had been considered at a NICE AC
and contained the base-case ICERs reported by manufacturers in
their submissions. Forty of these STAs also included base-case
ICERs reported by the ERGs. We analyzed pairs of base-case ICERs
estimated in these 40 STAs using four categories (costs given in
British pounds): £20,000 per quality-adjusted life year (QALY)
gained; £20,000 and £30,000 per QALY gained; £30,000 per
QALY gained; and £100,000 per QALY gained. Simple descriptive
analyses revealed that in 58% of STAs (23/40), the manufacturer
and the ERG ICERs were within the same category; in 10 STAs the
base-case ICER was estimated to be £20,000 per QALY gained, in
11 STAs it was estimated to be£30,000 per QALY gained; and in 2
STAs it was estimated to be between £20,000 and £30,000 per QALY
gained. In the remaining 17 STAs the ERGs base-case ICER was
always higher than the manufacturers’ base-case ICER.
For three STAs, a clear figure for the base-case ICER was not
estimated by the ERG. One ERG simply stated that a £30,000 per
QALY threshold analysis had been conducted [15]; one ERG re-
port estimated two base-case ICERs (one was more than £30,000
per QALY gained and the other more than £100,000 per QALY
gained [16]); one ERG report stated that the ERG was unable to
provide revised ICERs due to inconsistencies in themanufactur-
Table 2 – NICE disease categories.
STA topics in NICE disease categories Frequency
Cancer 46
Musculoskeletal 15
Digestive system 13
Respiratory 11
Cardiovascular 9
Therapeutic procedures 7
Skin 7
Central nervous system 5
Endocrine, nutritional and metabolic 4
Infectious diseases 3
Blood and immune system 2
Gynecology, pregnancy and birth 2
Eye 1
Injuries, accidents and wounds 1
Mental health and behavioral conditions 1
Public health 1
Urogenital 1
Note: some topics were listed in more than one category.
NICE, National Institute for Health and Clinical Excellence; STA,
single technology appraisal.er’s model [17].Appraisal committee decisions – YES, NO, minded NO
Our original report [12] provides information related to decision
aking on 43 STAs that had been through a first AC meeting. We
ave since updated the analysis of AC decisions and now provide
nformation on 50 STAs for which a final FAD has been issue (data
ere extracted in February 2011). Figure 2 provides the details of 50
STAs that were considered by the AC through to the FAD. Of the
original 95 topics considered in our analyses, 14 were still in prog-
ress and a final FAD had not yet been issued for any of these STA
topics.
Nine of the 50 STAs with FADs had been the subject of an
appeal. Of the remaining 41 STAs, 17 went from ACD to FAD with
the same decision (7 NO and 10 YES). Clearly for these STAs con-
sultation took place, but the decision taken did not change. For
three STAs, multiple decisions for different indications were is-
sued in the ACD (YES and minded NO) – two STAs had YES in the
FAD and one had a YES andNO in the FAD. To illustrate, in the STA
“Rituximab for the treatment of relapsed or refractory stage III or
IV follicular non-Hodgkin’s lymphoma [18]” the AC issued three
decisions in the ACD and three decisions in the FAD for rituximab
as follows: 1) monotherapy in the maintenance setting (ACD YES;
FAD YES); 2) in combination for patients with relapsed disease
(ACDminded NO, YES; FAD YES); and 3) monotherapy for patients
who could not tolerate chemotherapy (ACDYES; FADYES). The AC
can approve a technology and issue a FAD without consideration
of further evidence (i.e., without issuing an ACD) Five STAs did not
have an ACD on the NICE Web site.
There were 16 STAs in which single decisions changed be-
tween issue of the ACD and the FAD. Seven STAs had minded NO
decision in theACDwhich changed toYES in the FAD; one STAhad
aminded NO in the ACD and a NO in the FAD; eight STAs had a NO
decision in the ACD which changed to YES in the FAD (decision
changed without an appeal hearing). In total, the AC issued 26
negative ACDs and asked either the ERG and/or the manufacturer
to provide or carry out additional analyses in 11 appraisals. This
means that 27% of topicswithout appeal hearings (11/41) had to be
dealt with in detail again by the AC at a later meeting. This indi-
cates that additional resources were used by both the ERG and/or
themanufacturer to prepare information and analyses considered
necessary by the AC. Of the 11 STAs with minded NO decisions,
nine became YES decisions, one became a NO decision, and mul-
tiple decisions were issued for one STA (including YES and NO) at
FAD.
Appeals
An official appeal process has been in place since the inception of
NICE and appeals can be based on one or more of the following
grounds [19]:
The Institute has failed to act fairly and in accordance with the Ap-
praisal Procedure set out in the Institute’s Interim Guidance to Manufac-
turers and Sponsors:
● The Institute has prepared Guidance which is perverse in the light of
the evidence submitted;
● The Institute has exceeded its powers.
Nine of the 50 STAs with FAD decisions went on to be the
subject of an appeal. These are shown in Table 3 [20-28].
Grounds for appeal were dismissed for six of the nine appeals
undertaken; this means that only three of the FAD decisions were
changed as the result of an appeal verdict. In the unsuccessful
appeals, one appellant appealed against a YES decision and in
another there was no change to the decision, only a slight change
to the wording in the FAD. In the remaining three STAs, decisions
were changed from a NO to YES with cost restrictions (n  2) and
rom NO to YES (n  1). The NICE Decision Support Unit was in-
volved in one of the STAs that went to (successful) appeal. The
i
i
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care professionals (n  4) and independently (n  3); manufactur-
ers were not involved as appellants in two of the appeals. In most
of the STAs thatwent to appeal (6/9), the base-case ICER submitted
by the manufacturer was lower than £20,000 per QALY gained. In
most of the STAs that went to appeal (7/9), the base-case ICER
estimated by the ERG was greater than £30,000 per QALY gained.
Discussion
This study presents an independentmapping exercise of the NICE
STA process from 2005 to 2009. The STA process has evolved sig-
nificantly within a short period of time. The STA process has dealt
with over 17 different disease topics and 27 manufacturers have
been involved in the process during this time. In terms of the
stated goal of timeliness the new process is faster but has not
consistently met the stringent criteria outlined in the STA process
guide. On the whole, most relevant information for this mapping
exercise was available on the NICE Web site and publicly accessi-
ble, although placement of data was sometimes inconsistent and
required individuals who were familiar with the site to search
through the Web site. The findings presented in this study are of
relevance to an international audience because the issues raised
here are relevant to health-care systems requiring an evidence
based approach to the allocation of financial resources.
The mapping exercise revealed that almost one third of STA
topics that are referred to NICE for consideration are suspended or
terminated usually early on in the STA process primarily because
of regulatory or licensing issues. Because all identified topics now
Fig. 2 – Tracking of NICE ACD process from first Appraisal Co
document; FAD, final appraisal determination; NICE, Nationgo through a scoping exercise, there is a significant investment of ftime and resources in topics that do not go on to be subject of an
appraisal. The scoping process is seen by NICE as critical to the
successful conduct of appraisals. Nevertheless, negotiation and
consultation between interested parties on the wording of the fi-
nal scope can often take considerable time. In some instances this
is appropriate as themanufacturermay in fact only be in the early
stages of applying for market authorization for the new technol-
ogy and NICE will be trying to match the pathways of the STA
process with anticipated European Medicines Agency (EMA) time-
lines. The matching of NICE and EMA timelines is difficult and
there aremany STA topics that have been scoped and begun and
then cancelled due to the challenges of the regulatory system
and this continues to be the case.
The STA process, once it officially begins, is by definition
shorter than theMTAprocess. Our analyses reveal, even assuming
no appeals, that the shorter STA timelines set by NICE are not
being met. The Barham [6] study of the first 18 STAs also found
that the time taken for STAswas short of the target set byNICE and
that referral times may be longer for STAs than for MTAs. The
data, however, indicate that the majority of STAs are conducted
quickly with only 2 or 3 weeks delay at each stage in the process
and that any lengthy delays are typically the results of events that
are outside of the control of NICE.
Timelines under which the appraisals considered in this map-
ping exercise were set in 2006 [9] and extensive changes have
taken place regarding many aspects of the STA process since that
time including the revision of the STAmethods guide [10] and the
ntroduction of scoping workshops. In addition, a process of clar-
fication now takes place within the ERG assessment time to allow
ittee Meeting to FAD. ACD, appraisal consultation
stitute for Health and Clinical Excellence.mm
al Inor the team to raise any issues in the MS with the manufacturer.
Table 3 – Appeals in the STA process.
STA Original decisions Outcome of appeal Action Appellant What happened after
the appeal?
Cetuximab  radiotherapy
(head and neck) [20]
No (ACD)¡No (FAD) Appeal upheld on
various points
Reassessment of evidence.
Manufacturer asked to
provide more
information
Manufacturer and medical
professionals
Yes (2nd ACD)¡ Yes
(2nd FAD)
Febuxostat (hyperuricemia,
gout) [21]
No (ACD)¡ Yes (FAD) Dismissed on all
points
N/A Manufacturer Original decision stands
Rituximab (chronic
lymphatic, relapsed) [22]
Yes (ACD), No (ACD)¡Yes
(FAD), Yes  research
(FAD)
Appeal upheld on
one point
Slight rewording of FAD Medical professionals Original decision stands
Erlotinib (lung cancer,
relapsed) [23]
No (ACD)¡No (FAD) Appeal upheld on
various points
Reassessment of evidence.
Decision support unit
involvement
Manufacturer and medical
professionals
No (2nd ACD)¡No (2nd
FAD)¡Yes with cost
restrictions (3rd
ACD)¡Yes with cost
restrictions (3rd FAD)
Pemetrexed (lung cancer,
relapsed) [24]
No (ACD)¡No (FAD) Dismissed on all
points
N/A Manufacturer Original decision stands
Bortezomib (multiple
myeloma) [25]
No  research (ACD)¡No
(FAD)
Appeal upheld on
various points
Reassessment of evidence Manufacturer and medical
professionals
Yes with cost
restrictions (2nd
ACD)¡Yes with cost
restrictions (2nd FAD)
Trastuzumab (breast
cancer) [26]
ACD unavailable¡Yes
(FAD)
Dismissed on all
points
N/A Primary care trust Original decision stands
Abatacept (rheumatoid
arthritis) [27]
No (ACD)¡No (FAD) Dismissed on all
points
N/A Manufacturer and medical
professionals
Original decision stands
Sorafenib (hepatocellular
cancer) [28]
No (ACD)¡No (FAD) Dismissed on all
points
N/A Manufacturer Original decision stands
ACD, appraisal consultation document; FAD, final appraisal determination; N/A, not applicable; STA, single technology appraisal.
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also been developed. NICE has introduced end-of-life criteria [29],
patient access schemes [1], and the opportunity for ACdecisions to
include conditional approval related to cost [30]. Working within
this evolving STA processmeans that it is not unexpected that the
conduct of STAs is sometimes difficult and that topics do not al-
ways run to time.
The AC is faced with the task of making difficult decisions
within tight timeframes. When there is no appeal the decision-
making process is inevitably shorter and less expensive. In our
analysis of 41 STAs without an appeal, just over 50% (22/41) ap-
peared to have gone through the process smoothly (i.e., without
any changes to the decision fromACD to FAD or with a FAD issued
without an ACD). The remaining 19 STAs were more problematic
because decisions did change from ACD to FAD. In the majority of
cases, minded NO decisions were changed to YES decisions. It is
worth noting that for the 50 STAs with FAD decisions included in
our analyses, 76% of decisions were positive although some did
include approvals with restrictions. The Clement et al. [31] study
compared decisions made by the Common Drug Review (CDR) of
Canada, the Pharmaceutical Benefits Advisory Committee (PBAC),
and NICE, which found that 87.4% of submissions were recom-
mended by NICE (174/199 of drugs in 97 appraisals including both
MTAs and STAs), 49.6% (60/121) by CDR, and 54.3% (153/282) by
PBAC. The authors suggest that the higher approval rate for NICE
may be due to the fact that NICE typically evaluated classes of
drugs that have had regulatory approval for a longer period and
that NICE’s approach involves the identification of subgroups for
which the uncertaintymight be lower and the cost per QALYmore
acceptable.
Reasons for delay in the STA process are often related to regu-
latory issues. Before the AC can make a final decision about a
product, the manufacturer must hold a marketing authorization
for use of the product in Europe. Timing of marketing authoriza-
tion decisions by the EMA for products taking part in the STA
process is not consistent. In some cases the product may have
already been approved before the scope is issued by NICE; in oth-
ers the application may be in process and the manufacturer can
only hope that the marketing authorization and the NICE process
timelineswillmatch up. In the case of the former itmaymean that
the time from approval to issue of the FADmight take longer than
anticipated. In the latter case, it may turn out that the manufac-
turer’s application for a licence is rejected by the EMA, in which
case the STA process is terminated even after the MS has been
received and the completed ERG report has been submitted to
NICE. Or it could be the case that marketing authorization is
awarded with much stricter criteria than has been applied for by
themanufacturer and/or described in the NICE scope, the MS, and
the ERG report. When this happens there is a need for resubmis-
sion of the evidence by the manufacturer and reconsideration by
the ERG and possibly by the AC [32].
The STA process has timeliness as a fundamental focus. The
stated goal [9] is to bring new and cost-effective treatments to
patients as soon as possible following regulatory approval of their
use. If it is (conservatively) assumed that marketing authorization
takes place just before submission of the MS, then themean num-
ber of working weeks between submission and issue of the FAD is
key to working out whether or not NICE has met its goal of time-
liness. Our mapping exercise has revealed that the FAD is likely to
be issued within 8 months of evidence being submitted by the
manufacturer (assuming no appeal). Appeals obviously poten-
tially delay an appraisal by several months and have been sug-
gested as themain cause of “NICE blight” [33]. Haycox [33] suggests
streamlining the appeals process as a potential way for NICE to
improve the speedwithwhich it evaluates new technologies. Con-
cerns have also been raised by Drummond and Sorenson [34] thatspeeding up NICE’s decision making processes even further may
make it a potentially less robust process.
Decision making in the STA process is closely linked with the
size of the ICERs estimated by the manufacturer and also the con-
sequences of any corrections or revisions to themodel parameters
and ICERs made by the ERG. Interestingly, this mapping exercise
reveals that more often than not, themanufacturers and the ERGs
tend to agree on the general size of the ICER. As most ICERs, how-
ever, are above the £20,000 per QALY gained NICE threshold, this
agreement does not facilitate the AC’s decision making. Where
there is disagreement in the size of the ICER, the manufacturer’s
estimate is always lower than the ERG’s estimate and these differ-
ences are largely due to the differing assumptions incorporated by
the manufacturer and the ERG in the economic model. This is not
surprising given that the role of themanufacturer is to present the
clinical and cost-effectiveness of a technology in its best light, and
the role of the ERG is to explore all aspects of the clinical and
economic data and provide, where appropriate, alternative prop-
ositions. Other research has also reported that manufacturers
may be over optimistic in the cost-effectiveness analyses of their
technologies [35,36].
Limitations
This article presents a snapshot of the results of the continually
evolving STA process. The data presented here are a reflection of
information posted on the NICEWeb site during the period of data
extraction; therefore any errors in the data on the Web site are
reflected in the results of the presented analysis. Even during data
extraction the number of STAs listed as “completed” changed due
to the application of end of life criteria and patient access schemes
among other factors. We, as researchers who continue to be in-
volved in the STA process, believe that the results are generaliz-
able to the current situation. The research groups that conducted
this mapping exercise are intimately involved in the STA process
and are familiar with the NICE Web site; however, even we were
challenged in our attempts to identify key data from it.
A number of the STAs included in the mapping exercise were
still on-going at the time of original data extraction (August 2009)
and we have updated the final outcome from the STAs (February
2011). It is interesting to note that 14 STAs are still in progress and
do not have FADs. This article presents a reflection of the data
available at that time and may not be an accurate reflection of
what currently happens in the STA process.
Further research
Three areas have been identified where further research is
needed. First, attempts must be made to align the NICE STA pro-
cess more closely with the EMA timelines for new technologies to
reduce delays and cancellations. Secondly, a furthermonitoring of
current and future STA timelines and decisions is recommended
to assess changes and trends. Finally, research is needed to deter-
mine which key factors impact on decision outcomes in the STA
process.
Conclusion
This study presents the first independent mapping exercise of the
NICE STA process. Although the new process is faster, it has not
consistently met the stringent timelines outlined in the STA pro-
cess guide [1]. Delays are at a minimum during the period when
NICE has control of the process. Positive decisions were given to
over three quarters of the technologies considered in the STA pro-
cess.
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